|
|
||||||||||||||
|
|
|||||||||||||||
REPORT |
Max-Planck-Institute for Infection Biology, Germany
Correspondence to:
Correspondence:
Professor S H E Kaufmann, Max-Planck-Institute for Infection Biology, Department of Immunology, Schumannstrasse 21-22, D-10117 Berlin, Germany;
kaufmann{at}mpiib-berlin.mpg.de
ABSTRACT
Tuberculosis remains a major health problem, with two million deaths and eight million new cases annually. At the same time, two billion people (one third of the total world population) are infected with the aetiological agent, Mycobacterium tuberculosis. Of these, fewer than 10% ever develop disease, although the pathogen is not eradicated but rather contained in discrete lesions. Hence, the immune system is highly effective in containing the pathogen, but fails to eradicate it. Disease typically develops through reactivation once the immune system is weakened. The immune response to M tuberculosis is T cell dependent. It comprises not only the conventional CD4 and CD8 T cells, but also 
T cells and CD1 restricted T cells. 
T cells recognise phospholigands and no presentation molecules are known thus far. CD1 restricted T cells recognise glycolipids, which are highly abundant components of the mycobacterial cell wall. Although different T cells are required for optimum protection, the immune mechanisms known to have a role in acquired resistance can be associated with two major mechanisms: (a) activation of macrophages by cytokines; (b) direct cytolytic activity. In vivo granuloma formation, which is central to protection, is induced and sustained by cytokines. Mycobacteria are contained within granulomas and in this way are prevented from spreading all over the body.
Keywords: tuberculosis; cytokines; T cells; macrophages
Abbreviations: HIV, human immunodeficiency virus; IFN
, interferon
; LT
, lymphotoxin
; MDR, multidrug resistant; MHC, major histocompatibility complex; TNF
, tumour necrosis factor 
This article has been cited by other articles:
![]() |
Y. J. Jeong and K. S. Lee Pulmonary Tuberculosis: Up-to-Date Imaging and Management Am. J. Roentgenol., September 1, 2008; 191(3): 834 - 844. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Phillips, C. Horsfield, J. Mangan, K. Laing, S. Etuaful, P. Awuah, K. Nyarko, F. Osei-Sarpong, P. Butcher, S. Lucas, et al. Cytokine mRNA Expression in Mycobacteriam ulcerans-Infected Human Skin and Correlation with Local Inflammatory Response. Infect. Immun., May 1, 2006; 74(5): 2917 - 2924. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Phillips, C. Horsfield, S. Kuijper, S. F. Sarfo, J. Obeng-Baah, S. Etuaful, B. Nyamekye, P. Awuah, K. M. Nyarko, F. Osei-Sarpong, et al. Cytokine Response to Antigen Stimulation of Whole Blood from Patients with Mycobacterium ulcerans Disease Compared to That from Patients with Tuberculosis Clin. Vaccine Immunol., February 1, 2006; 13(2): 253 - 257. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A. Tree, M. J. Elmore, S. Javed, A. Williams, and P. D. Marsh Development of a Guinea Pig Immune Response-Related Microarray and Its Use To Define the Host Response following Mycobacterium bovis BCG Vaccination Infect. Immun., February 1, 2006; 74(2): 1436 - 1441. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Sakthianandeswaren, C. M. Elso, K. Simpson, J. M. Curtis, B. Kumar, T. P. Speed, E. Handman, and S. J. Foote The wound repair response controls outcome to cutaneous leishmaniasis PNAS, October 25, 2005; 102(43): 15551 - 15556. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. A. Roberts, A. Clark, S. McBeth, and R. L. Friedman Molecular Characterization of the eis Promoter of Mycobacterium tuberculosis J. Bacteriol., August 15, 2004; 186(16): 5410 - 5417. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. L. Fuller, J. L. Flynn, and T. A. Reinhart In Situ Study of Abundant Expression of Proinflammatory Chemokines and Cytokines in Pulmonary Granulomas That Develop in Cynomolgus Macaques Experimentally Infected with Mycobacterium tuberculosis Infect. Immun., December 1, 2003; 71(12): 7023 - 7034. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |